جست‌وجوی استاد و پژوهشگر

David Monkمشاهده پروفایل

استاد

• Developmental Epigenetics
• Genomic Imprinting
• DNA Methylation
• +۷ مورد دیگر

David Monk is Professor of Developmental Epigenetics at the University of East Anglia, School of Biological Sciences, where he also serves as the Cells & Tissues Theme Leader. His research focuses on epigenetic mechanisms in human development and disease, with emphasis on genomic imprinting, DNA methylation, and placental biology. Research Interests: His work investigates how epigenetic regulation influences fetal growth, imprinting disorders, and cancer. He employs high-throughput genomic technologies, single-cell epigenomics, and genome editing to dissect the interplay between genetic variation and epigenetic marks, especially in early development and placental function. Recent Research Trends: His most recent publications (2023–2025) highlight a strong focus on placenta-specific imprinting, non-canonical methylation patterns, transcriptomic alterations in complicated pregnancies, and epigenetic defects in early embryonic development. The integration of single-cell multi-omics and low-input profiling is a recurring methodological theme. Scientific Awards: Ramon y Cajal Career Development Fellowship Grants and Advising: He leads multiple active research projects funded by the BBSRC, MRC, and NHS-affiliated trusts. While specific students are not listed, his publications indicate active mentorship of researchers in epigenetics and developmental biology. Labs and Teams: He leads a research team at UEA focused on developmental epigenetics, and collaborates with international institutions, including IDIBELL (Barcelona), and clinical partners such as Norfolk & Norwich University Hospitals NHS Foundation Trust.

Chi Wangمشاهده پروفایل

استاد

• Cancer Biostatistics
• Bioinformatics
• Survival Analysis
• +۱۰ مورد دیگر

Chi Wang, Ph.D., is Professor of Internal Medicine and Statistics at the University of Kentucky, Associate Director of the Biostatistics & Bioinformatics Shared Resource, and a lead computational scientist within the Markey Cancer Center. With an h-index of 39 and >5,300 citations, he develops cutting-edge survival-analysis and high-dimensional-omics methods that are translated into prostate, breast, lung and neuroblastoma trials. Education: Ph.D. Biostatistics, Johns Hopkins University, 2009 M.S. Statistics, Peking University, 2003 B.S. Mathematics, Peking University, 2001 Research Focus: Wang’s group integrates Bayesian statistics, machine-learning and single-cell sequencing to model tumor evolution, drug resistance and biomarker-driven adaptive trials. Major themes include enzalutamide resistance in prostate cancer, PLK1-mediated immune evasion in lung adenocarcinoma, obesity-adipose drivers of breast cancer, and epigenetic reprogramming of tumor-infiltrating lymphocytes. Recent Article Trends (2023-2025): Fifteen showcased papers reveal a dual trajectory—(1) mechanistic dissection of kinases (PLK1, DDR1, ABL1/2) and metabolic enzymes (FASN, NNMT, HSP47) that orchestrate resistance and metastasis, and (2) probabilistic algorithms for temporal mutation ordering, biomarker evaluation and single-cell deconvolution. Overarching keywords are precision oncology, drug resistance, tumor micro-environment, and computational systems biology. Funding & Awards: He is PI/co-I on 152 grants (32 active) from NCI, ACS, V Foundation, etc., totaling >$30 M direct costs. Highlights include NCI U01 for predictive biomarkers, American Cancer Society award on collagen lysyl hydroxylase metastasis drivers, and NCI R01s targeting NNMT in triple-negative breast cancer and TIL epigenetic reprogramming in NSCLC. Student & Team Mentorship: Wang trains a large multi-disciplinary cohort of Ph.D. students, post-docs and clinical fellows who routinely lead first-author papers and are funded on his grants. His lab sits within the Markey Cancer Center’s Molecular & Cellular Oncology program and the Center for Computational Sciences, fostering daily bench-to-bedside collaboration.

Bina Joeمشاهده پروفایل

استاد

• Physiological Genomics
• Hypertension
• Gut Microbiome
• +۳ مورد دیگر

Bina Joe , Ph.D., is a Distinguished University Professor and Chair of the Department of Physiology and Pharmacology at the University of Toledo College of Medicine and Life Sciences. She serves as the Founding Executive Director of the Center for Hypertension and Precision Medicine and Principal Investigator of the Program in Physiological Genomics. With appointments at the University of Toledo since 2004 and current roles in leadership and research, her work bridges genetic, physiological, and microbiome-based mechanisms in cardiovascular diseases. Research areas include hypertension genetics, gut microbiome-cardiovascular links, and precision medicine Key methodologies: systems biology, CRISPR engineering, and microbiome profiling Scientific Awards & Honors Fellow of the American Heart Association (FAHA, 2010) Distinguished University Professor (2017) President’s Awards for Excellence in Grantsmanship (2019, 2017, 2015) Ernest Starling Distinguished Lectureship (2022) Over 20 national/international awards and fellowships Her research team utilizes rat models to dissect genetic and microbiotal contributions to hypertension, with translational applications in human disease. Recent work emphasizes gut microbiota-diet-host interactions, epigenetic mechanisms (e.g., histone β-hydroxybutyration), and novel therapeutic targets for metabolic and cardiovascular disorders. Publications span top-tier journals like Cell , Nature Communications , and Physiological Genomics , with recurring themes of sex-specific regulation and microbiome engineering.

• Systems Biomedicine
• Neurodegenerative Diseases
• Computational Modelling
• +۶ مورد دیگر

Alexander SKUPIN is an Associate Professor and Chief Scientist in the Luxembourg Centre for Systems Biomedicine (LCSB) at the University of Luxembourg, specializing in Modelling of Biomedical Data. His research focuses on computational systems biology, neurodegenerative diseases, and integrative multi-omics analysis. Key research interests include modeling cellular energy metabolism, microglial dynamics in neurodegeneration, and calcium signaling dysfunction in Parkinson’s and Alzheimer’s diseases. His work combines experimental data with advanced computational methods to dissect disease mechanisms and predict therapeutic targets. Recent publications highlight innovations in: Sex-specific transcriptomic changes in tauopathy models Computational models of astrocytic morphology and mitochondrial efficiency Multi-omics integration for Parkinson’s disease intervention points Epidemiological modeling using Kalman-filtered SIRS networks No scientific awards explicitly mentioned. Advising and grants: No specific advisees or grant details listed, but his work implies leadership in collaborative projects involving organoid models and patient-derived xenografts. Labs/Teams: Part of LCSB’s Integrative Cell Signalling group, collaborating on systems biomedicine initiatives involving computational modeling and experimental validation.

John Aitchisonمشاهده پروفایل

استاد مدعو

• Systems Biology
• Cell Biology
• Systems Cell Biology
• +۷ مورد دیگر

John Aitchison is an Adjunct Professor affiliated with the Institute for Systems Biology and the Center for Infectious Disease Research in Seattle, Washington. He holds a Ph.D. from McMaster University and leads a research program in systems cell biology, focusing on the integration of molecular, genomic, and computational approaches to understand cellular complexity. Adjunct Professor, Institute for Systems Biology, Seattle Ph.D., McMaster University Dr. Aitchison’s research centers on systems cell biology, with key interests in nucleocytoplasmic transport, peroxisome biogenesis, and host-pathogen interactions. His lab employs functional genomics, proteomics, and computational modeling to dissect the molecular mechanisms underlying cellular organization and responses to environmental stimuli. He collaborates extensively with the Rachubinski and Wozniak laboratories at the University of Alberta. His recent publications reflect a strong focus on systems-level analyses of cellular processes, including gene regulation, chromatin dynamics, and immune responses to infection. Trends in his work include the development of integrative models to predict cellular behavior and the study of organelle dynamics in health and disease. CIHR Scholar AHFMR Scholar Dr. Aitchison has mentored numerous postdoctoral fellows and research scientists, including Fred Mast, Song Li, and Thurston Herricks. His lab has received support from various funding agencies, enabling large-scale proteomic and genomic studies. He also contributes to scientific discourse through editorial roles, as seen in his commentary on MBoC. His laboratory operates at the intersection of experimental and computational biology, developing and applying high-throughput technologies to address fundamental questions in cell biology and infectious disease.

• Amyotrophic Lateral Sclerosis (ALS)
• Frontotemporal Dementia (FTD)
• Stem Cell Research
• +۵ مورد دیگر

Ruxandra Dafinca is a Brain Science Research Fellow and Group Leader at the Nuffield Department of Clinical Neurosciences (NDCN), University of Oxford, where she leads research within the Oxford Motor Neuron Disease Centre. Her work focuses on unraveling molecular mechanisms in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) using cutting-edge patient-derived stem cell models. Her educational background includes: MSc DPhil Dr. Dafinca's research program investigates intracellular signaling pathways leading to synaptic deficiencies in ALS/FTD through spatial proteomics , transcriptomics , and live imaging of patient-induced pluripotent stem cell (iPSC)-derived neurons. She pioneered iPSC differentiation to motor and cortical neurons in 2013, establishing critical models for studying C9ORF72 hexanucleotide expansions and TDP-43 proteinopathies . Her work targets therapeutic discovery by identifying regulatory pathway disruptions in neurodegenerative processes. Analysis of her 15 most recent publications (2020-2025) reveals dominant themes in C9ORF72-related ALS/FTD mechanisms , mitochondrial dysfunction , axonal transport defects , and neuroinflammation . Key methodologies include high-throughput drug screening, CRISPR genome editing, and multi-omics integration, with strong translational emphasis on biomarker discovery and personalized drug evaluation for ALS therapeutics. Her research is funded by major grants from the My Name'5 Doddie Foundation , Motor Neuron Disease Association , and Oxford University's John Fell Fund and Medical Sciences Division Pump-Priming Award . She actively recruits postdoctoral researchers for multi-omics and microfluidics projects, indicating active mentorship in advanced neurodegenerative disease modeling. Dr. Dafinca collaborates extensively within the Oxford Motor Neuron Disease Centre alongside Professor Kevin Talbot (Head of Department), Associate Professor Martin Turner, and Professor Elizabeth Gray. Her laboratory leverages iPSC co-culture systems and advanced imaging to dissect neuron-microglia interactions and develop novel therapeutic strategies for ALS/FTD.

Siyuan Wangمشاهده پروفایل

دانشیار

• 3D Genomics
• Spatial Multi-Omics
• Chromatin Architecture
• +۴ مورد دیگر

Siyuan (Steven) Wang, an Associate Professor at Yale University's School of Medicine, holds dual appointments in Genetics and Cell Biology. His research focuses on 3D genomics, spatial multi-omics, and chromatin architecture. He pioneered the 'chromatin tracing' method and developed the MINA platform for nucleome imaging. Key contributions include studies on X chromosome folding, cancer genome evolution, and aging mechanisms. Education: B.Sc. in Physics from Peking University (2007), Ph.D. in Molecular Biology from Princeton University (2011), postdoctoral training at Harvard University (2011–2017). His lab integrates imaging, genetics, and computational tools to dissect genome organization in health and disease. Research highlights include resolving single-cell 3D genome maps in cancer, discovering regulators of chromatin architecture via Perturb-tracing, and mapping senescent cell dynamics in aging tissues. Awards include the NIH Director’s New Innovator Award (2019–2024) and ASCB Innovation in Research Award (2024). Labs/Teams: Directs the Siyuan Wang Lab at Yale, collaborating with institutions like the NIH SenNet Consortium. Ongoing work explores spatial transcriptomics and functional regulators of chromatin in disease contexts.

Eleftheria Zegginiمشاهده پروفایل

استاد

• Translational genomics
• Cardiometabolic diseases
• Type 2 diabetes
• +۵ مورد دیگر

Eleftheria Zeggini is a Professor at the Technical University Munich (TUM) School of Medicine and Health and the founding Director of the Institute of Translational Genomics at Helmholtz Munich, Germany. Her research focuses on leveraging big biomedical data to translate genomics insights into mechanisms of disease development and progression, advancing precision medicine. Education PhD in Genetic dissection of the MHC in juvenile oligoarthritis (University of Manchester, UK, 2003) BSc (Hons) in Biochemistry (UMIST, UK, 1999) Her research spans translational genomics , cardiometabolic diseases , type 2 diabetes , osteoarthritis , and digital health . She has secured significant grants from organizations like the German Research Foundation (DFG), Helmholtz Munich, Wellcome Trust, and European Research Council (ERC). Her work integrates multi-omics approaches, single-cell technologies, and population genetics to address complex diseases. Notable scientific awards include ERC Starting Grant , EMBO membership , ELLIS Fellowship , and multiple Web of Science Highly Cited Researcher recognitions. She has held leadership roles in academic advisory boards across Europe and Africa.

Sandra Pohlمشاهده پروفایل

استاد

• Lysosomal storage disorders
• Mucolipidosis type II and III
• Osteogenesis imperfecta
• +۵ مورد دیگر

Prof. Dr. Sandra Pohl is a full Professor at the University Medical Center Hamburg-Eppendorf (UKE), affiliated with the Department of Osteology and Biomechanics. Her research focuses on lysosomal storage disorders, particularly mucolipidosis types II and III, and their systemic effects on bone, cartilage, kidney and the central nervous system. She employs mouse models, human genetic studies and translational approaches to dissect disease mechanisms and develop therapeutic strategies. Education & Training No specific educational details provided in the source material; only the academic title "Prof. Dr. (PhD)" is listed. Research Interests Prof. Pohl’s work centers on: Molecular pathology of mucolipidosis type II (I-cell disease) and type III (pseudo-Hurler polydystrophy). GlcNAc-1-phosphotransferase biology and its role in lysosomal enzyme targeting. Skeletal manifestations of lysosomal storage disorders, including osteopenia, cartilage degeneration and dysostosis multiplex. Neurocognitive outcomes and CNS imaging in mucolipidosis patients. Enzyme replacement therapy design and evaluation in pre-clinical mouse models. Proteostasis, autophagy and ubiquitin-proteasome system interactions in disease pathogenesis. Publication Trends Between 2020 and 2024, Prof. Pohl has published extensively on the intersection of lysosomal dysfunction and skeletal/renal/neurological pathology. Her recent articles emphasize: Genotype–phenotype correlations in GNPTAB/GNPTG variants. Translational mouse models recapitulating human mucolipidosis. Multi-omics profiling (proteomics, imaging, metabolomics) to uncover disease biomarkers. Interdisciplinary studies linking basic cell biology to clinical manifestations. Research Support & Collaborations Prof. Pohl currently leads or co-leads the following initiatives: SFB 877, Teilprojekt B03: “Proteolysis-ver” (exact title abbreviated in source) – a collaborative research center funded by the German Research Foundation (DFG). Cross-institutional consortia involving nephrologists, neurologists, geneticists and imaging specialists across Germany and internationally. Laboratory & Core Facilities Her team utilizes state-of-the-art core facilities provided by UKE, including: Transgenic mouse core Advanced imaging and microscopy Mass-spectrometry-based proteomics High-throughput sequencing and bioinformatics platforms

• colon cancer
• liver cancer
• pancreatic cancer
• +۱۴ مورد دیگر

Mirela Sedić, Ph.D. is a senior scientific associate at the Institute for Anthropological Research in Croatia, with extensive research experience in cancer biology and therapy. She has authored over 50 scientific publications in high-impact journals such as BBA Molecular Basis of Disease, Molecular Cancer, The Journal of Pathology, and others, with her work cited 1286 times (h-index 17; i10-index 30). Dr. Sedić serves as a reviewer for numerous international scientific journals and holds editorial board positions with Global Journal of Cancer Therapy, American Journal of Pharmacology & Therapeutics, Current Cancer Therapy Reviews, Clinical Cancer Drugs, and BMC Cancer. Dr. Sedić's research spans multiple critical areas in oncology, with particular focus on gastrointestinal cancers including colon, liver, and pancreatic cancer. Her work investigates cancer cell signaling pathways, mechanisms of chemoresistance, and novel therapeutic approaches including drug repurposing and combination treatments. She employs advanced techniques such as mass spectrometry-based proteomics and lipidomics, combined with bioinformatics analysis, to dissect complex cancer biology phenomena. Analysis of Dr. Sedić's recent publication record reveals a strong emphasis on understanding therapy resistance in BRAF-mutant colon cancer, with particular attention to sphingolipid metabolism pathways. Her research has increasingly incorporated multi-omics approaches to identify potential therapeutic targets and develop strategies to overcome resistance to targeted therapies like vemurafenib. Dr. Sedić has received significant recognition through multiple scientific honors: International patent WO/2010/052510 Appointment as expert evaluator for EU Framework Programs (FP7, HORIZON 2020, Horizon Europe) since 2012 Editorial Board membership with five prominent cancer research journals As a principal investigator, Dr. Sedić has secured competitive funding for multiple significant research projects, including a Croatian Science Foundation project (2019-2023), University of Rijeka research grants, and international collaborations with institutions like the Functional Genomics Center Zurich. Her consistent success in obtaining research funding demonstrates the significance and impact of her work in advancing our understanding of cancer biology and therapy.

• Translational Genomics
• Statistical Genetics
• Computational Genomics
• +۴ مورد دیگر

Eleftheria Zeggini serves as Director of the Institute of Translational Genomics at Helmholtz Munich and holds the Liesel Beckmann Distinguished Professorship and Chair of Translational Genomics at the Technical University of Munich (TUM) School of Medicine. Her research leverages big data in genetics and genomics to translate genomic insights into disease mechanisms, advancing precision medicine through robust statistical and computational approaches integrating multi-omics data, electronic health records, and diverse population studies. Her educational background includes a PhD in Immunogenetics of Juvenile Arthritis from the University of Manchester School of Medicine (2003) and a Bachelor of Science (Hons) in Biochemistry from the University of Manchester Institute of Science and Technology (1999). Prior appointments include Group Leader at the Wellcome Sanger Institute (2008-2018) and Wellcome Research Career Development Fellow at the University of Oxford (2006-2008). Zeggini's research spans translational genomics, statistical genetics, and computational biology with emphasis on genetic architecture of complex diseases. Her team develops tools for multi-omics integration to dissect sequence variation in human health, focusing on osteoarthritis, type 2 diabetes, and cardiometabolic disorders. Recent work prioritizes health equity through tissue-specific multi-ancestry genomic studies and electronic health record integration, driving discovery of novel therapeutic targets and disease mechanisms. Analysis of her 15 most recent publications reveals dominant themes in osteoarthritis genomics (6 articles), type 2 diabetes heterogeneity (3 articles), and multi-ancestry genomic equity (3 articles). Her work consistently employs whole-genome sequencing, causal inference methods, and large-scale biobank analyses across diverse populations, with strong translational focus on precision medicine applications. Major scientific recognition includes: Elected Member of Academia Europaea (2024) Greek Excellence Award (2024) National Representative to the EMBL Council (2022) Elected Fellow of the Academy of Medical Sciences, UK (2020) Argo Award for Distinguished Greeks Abroad (2020) Honorary Senior Fellow, University of Cambridge (2018) Honorary Professor, University of Bristol (2018) Zeggini actively mentors early-career researchers while promoting diversity and inclusion in science. Her leadership in major consortia like UK Biobank analyses and ENABLE program demonstrates sustained grant acquisition capability. Current research direction focuses on developing computational frameworks for next-generation translational genomics, with particular emphasis on addressing health disparities through equitable genomic data representation. She directs Helmholtz Munich's Institute of Translational Genomics, which houses a multidisciplinary team of computational biologists, geneticists, and clinicians developing statistical tools for big data integration. The institute serves as a hub for precision medicine innovation, collaborating with TUM's medical faculty and international networks to accelerate genomic discoveries into clinical applications.

Gunvant Baliram Patilمشاهده پروفایل

استادیار

• Genetic Engineering
• Translational Genomics
• Genome Editing
• +۱۲ مورد دیگر

Dr. Gunvant Baliram Patil is an Assistant Professor at Texas Tech University, jointly affiliated with the Institute of Genomics for Crop Abiotic Stress Tolerance (IGCAST) and the Department of Plant and Soil Sciences. His research focuses on advancing genetic engineering and genomics to improve crop resilience and productivity. Institution: Texas Tech University School: Institute of Genomics for Crop Abiotic Stress Tolerance Department: Department of Plant and Soil Sciences Position: Assistant Professor Email: gunvant.patil@ttu.edu Office: 210B, Experimental Science Building II Dr. Patil holds a B.S. from North Maharashtra University, India, an M.S. and Ph.D. from the University of Pune and National Center for Plant Biotechnology, New Delhi. He previously served as a research scientist at the University of Minnesota-St. Paul, a postdoctoral associate at the University of Missouri-Columbia, and a visiting researcher at the Swedish University of Agricultural Sciences. His research interests include genetic engineering, genome editing, translational genomics, and crop improvement under abiotic stress. He aims to develop genotype-independent transformation systems in recalcitrant crops such as soybean, cotton, and sorghum. His lab integrates CRISPR/Cas9, single-cell transcriptomics, and high-throughput phenotyping to dissect molecular mechanisms of stress tolerance and nutrient uptake. The recent publications reflect a strong focus on soybean genomics, stress response mechanisms, and gene-editing technologies. Trends include the use of RNA-Seq, CRISPR-based editing, and functional characterization of gene families (e.g., SWEET, TIP, XIP) involved in transport, stress, and defense. His work increasingly emphasizes tissue culture-free editing and single-cell resolution in plant systems. 2nd place in Oral Presentation at PSS-Symposium-2024 (mentored student) 3rd place in Oral Presentation at SICNA Conference 2024 (mentored student) USDA – Sustainable Agriculture Research and Education Grant (mentored student) Dr. Patil advises multiple graduate students and postdoctoral researchers and leads a dynamic research team at the Patil Lab. His research is supported by grants from USDA-NIFA, United Soybean Board, Southern Soybean Research Program, and TTU-BASF (Project Revolution). He teaches graduate courses such as PSS5325: Transgenic and Plant Cell Genetics, emphasizing CRISPR, gene silencing, and recombinant DNA technology. The lab is actively involved in projects on nutrient uptake efficiency, regeneration system development, and durable resistance to soybean cyst nematode. The team utilizes cutting-edge tools like protoplast transformation, single-nucleus RNA sequencing, and high-throughput phenotyping to achieve translational outcomes in crop improvement.

Yasser Aldhamenمشاهده پروفایل

دانشیار

• Immunology
• Cancer Therapeutics
• Gene Therapy
• +۵ مورد دیگر

Yasser Aldhamen is an Associate Professor in the Department of Microbiology and Molecular Genetics at Michigan State University’s College of Natural Science. His research focuses on developing immunotherapies targeting cancer and infectious diseases, particularly leveraging innate immune system mechanisms and T cell regulation. Dr. Aldhamen holds a Ph.D. in Microbiology and Molecular Genetics from MSU, an MBA from Eli Broad Graduate School of Management, and a master’s in Molecular Basis of Disease from the University of Toledo. His lab investigates tumor microenvironment dynamics, SLAMF7 signaling in T cell exhaustion, and ERAP1’s role in immune regulation. Recent work highlights the anti-tumor efficacy of Ad5-SLAMF7-Fc vectors and the protective role of meningeal IL-10 in pain relapse. Dr. Aldhamen’s research spans virotherapy, gene delivery systems, and computational drug discovery, with a focus on translating findings into clinical applications. Key research trends include: 1) engineering immunomodulatory proteins to enhance antitumor responses, 2) dissecting cytokine networks in autoimmune diseases, and 3) developing AI-driven high-throughput screening methods. His work bridges basic immunology with translational medicine, emphasizing molecular mechanisms and therapeutic translation. Laboratory activities involve adeno-associated viral vector design, in vitro/in vivo immune profiling, and preclinical testing of novel therapeutic platforms. Future directions include refining SLAMF7-based therapies and exploring ERAP1’s role in autoimmunity through multi-omics approaches.

• Nutrigenomics
• Lipid Metabolism
• Inflammatory and Oxidative Processes
• +۶ مورد دیگر

Valérie Marcil is an Associate Professor in the Department of Nutrition at the Faculty of Medicine, University of Montreal , and a researcher at the CHU Sainte-Justine Research Center . Her work bridges clinical research and nutrigenomics, focusing on metabolic and inflammatory processes in pediatric cancers, inflammatory bowel diseases, and adolescent idiopathic scoliosis. Academic rank: Associate Professor Email: valerie.marcil@umontreal.ca Research Interests : Dr. Marcil investigates cardiometabolic complications in childhood cancer survivors, exploring how epigenetics , intestinal microbiota , and oxidative stress contribute to late effects. She also examines the gut-brain-bone axis in scoliosis and develops personalized nutritional therapies for disease prevention. Recent Article Trends : Her 2023-2024 publications emphasize lipid metabolism , pediatric oncology , and metabolic syndrome in cancer survivors. Key subfields include HDL dysfunction , early nutritional interventions , and omega-3 fatty acid applications . Scientific Awards : Prix d'excellence en enseignement aux cycles supérieurs (2022, 2019) International ACG Presidential Poster Awards (2010, 2009) FRQS and CIHR research fellowships Strauss Foundation postdoctoral grant Laboratory & Teams : Director of the Department of Nutrition at the University of Montreal, she leads the VIE Project (Valorisation, Involvement, Education) for integrated cancer care and the PROBI-O-TISM study on probiotic interventions in autism-related behaviors. Her lab employs animal models and multi-omics approaches to dissect metabolic-disease mechanisms.

Jonathan Keatsمشاهده پروفایل

استادیار

• Multiple Myeloma
• Cancer Genomics
• Bioinformatics
• +۴ مورد دیگر

Jonathan Keats, Ph.D., serves as an Assistant Professor at the Translational Genomics Research Institute (TGen) and holds the position of Scientific Director at the Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope. Additionally, he directs TGen's Bioinformatics division and the Collaborative Sequencing Center, which provides advanced genomic sequencing services to researchers worldwide. His work bridges cutting-edge genomics with clinical applications in cancer. Dr. Keats' educational journey includes: Ph.D. from the University of Alberta (2005), where he investigated the clinical and biological consequences of the t(4;14)(p16;q32) translocation in multiple myeloma under Dr. Linda Pilarski. Postdoctoral training at the Mayo Clinic with Dr. Leif Bergsagel, focusing on identifying novel genetic events in multiple myeloma pathogenesis. His research is predominantly centered on multiple myeloma, with secondary interests in other hematological malignancies and immunodeficiency syndromes. Dr. Keats employs innovative genomic and bioinformatic methodologies to dissect the molecular underpinnings of these diseases, particularly targeting pathways like NF-kB that drive tumor development, progression, and therapeutic resistance. His work aims to translate genomic discoveries into immediate clinical impact, aligning with TGen's ethos of 'helping someone today.' Analysis of Dr. Keats' publication record reveals a trajectory from early investigations of specific cytogenetic abnormalities (e.g., t(4;14)) to comprehensive genomic analyses. His landmark studies include the identification of NF-kB pathway mutations and participation in the Multiple Myeloma Genomics Initiative. Recent work leverages advanced sequencing technologies to uncover structural variants and epigenetic modifications, demonstrating a consistent focus on integrating multi-omics data to refine disease subtyping and identify therapeutic vulnerabilities in myeloma. Dr. Keats leads the Collaborative Sequencing Center at TGen, which utilizes state-of-the-art short-read, long-read (Oxford PromethION), and intermediate-read sequencers to provide gapless human genome assemblies. His laboratory at the Briskin Center conducts research on multiple myeloma genomics and is the lead site for the CoMMpass study, which has identified distinct myeloma subtypes based on genomic profiles. This work directly informs precision medicine approaches for myeloma patients.